Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novoste 40 mm Seed Train Addresses Clinical Concern Over "Edge" Effect

This article was originally published in The Gray Sheet

Executive Summary

Novoste plans to introduce into ongoing European and U.S. clinical trials this quarter a longer seed train for the Beta-Cath radiotherapy catheter system, which is intended to prevent possible restenosis at the edge of the treatment zone of a coronary vessel.

You may also be interested in...

Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial

Novoste Corp. is considering further evaluation of its Beta-Cath radiation system using a longer source train and a smaller diameter catheter in conjunction with initial angioplasty treatment.

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts